The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Study critique · continued

A well-designed study with a badly written abstract posts 121–129

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

CI
c.inglethorpeTL3Regular1 Jun 2025#121
buffer_shift, post #104: What makes a methodological criticism substantive: it identifies a specific feature of the design that materially affects what the paper can conclude. "Small sample size" alone is weak. "Small sample size for a rare outcome, so the confidence interval is wide" is stronger. Go to post

Choosing the worst interpretation: "The confidence interval includes a harmful effect" is true if the CI goes from -1 to +5. But assuming the worst-case scenario is not how you use the evidence. The point estimate and the precision both matter.

0 likes in reply to #104 14mo
HB
h.bhattacharyaTL2 Moderator1 Jun 2025#122
s.vukovic, post #78: This follows post #75 rather than contradicting it. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am… Go to post

Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished negative trials is a fair critical question.

19 likes in reply to #78 14mo
C
CSagredoTL3Regular2 Jun 2025#123

Multiple comparisons: if a paper reports many outcomes, the chance of a spurious association by random chance is real. Pre-specification of primary outcomes matters and secondary analyses are weaker evidence.

5 likes 14mo
HR
h.ramosTL2 Moderator2 Jun 2025#124

post #123 is right about the mechanism and I think understates the practical bit.

Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished negative trials is a fair critical question.

0 likes 14mo
OA
o.abrahamsenTL3Regular2 Jun 2025 · edited#125
a.batista, post #94: When you change your mind: if a reply convinces you that your criticism was not well-founded, say so plainly. The critique might still be real but smaller than you originally thought. That is not a failure — it is how discussion works. Go to post

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

28 likes in reply to #94 14mo
MN
m.nwosuTL2 Moderator3 Jun 2025#126

What makes a methodological criticism substantive: it identifies a specific feature of the design that materially affects what the paper can conclude. "Small sample size" alone is weak. "Small sample size for a rare outcome, so the confidence interval is wide" is stronger.

13 likes 14mo
EK
e.kjeldsenTL2Member3 Jun 2025#127

On post #123 — agreed on the reasoning, with one qualification.

Defending a paper against criticism: if the authors respond, they might clarify something the paper explained poorly. Their response might also miss your point. Either way, the exchange in public is more useful than quiet disagreement.

2 likes 14mo
PL
p.lindqvistTL2 Moderator4 Jun 2025#128

post #127 answers the question as asked. The question underneath it is different.

Building consensus on which criticisms matter: if everyone agrees that the sample size is small but only you think that affects the conclusion, maybe your criticism is more idiosyncratic. That does not make it wrong but it is worth noticing.

0 likes 14mo
BD
b.demirTL2 Moderator4 Jun 2025#129
n.serrano, post #10: Worth separating two things that post #6 runs together. What makes a methodological criticism substantive: it identifies a specific feature of the design that materially affects what the paper can conclude. "Small sample size" alone is weak. "Small sample size for a rare outcome, so the confidence interval is wide" is stronger. Go to post

I read post #127 twice before replying, because I had assumed the opposite.

Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative statistical analysis might bias toward null.

20 likes in reply to #10 14mo

Suggested topics

TopicParticipantsRepliesViewsActivity
Coming back to: Measurement error in a self-reported exposure
Measurement error in a self-reported exposure — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
LARNOAKACD+23 27 49k 3mo
Selection into a registry and what it does to the estimate
Selection into a registry and what it does to the estimate — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
SSLMAA 2 55k 7mo
A claim built entirely on a subgroup analysis — what changed since
On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
AWZCQZ 2 2k 18mo
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim…
KBZOKOJMTV+55 61 60k 15mo
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
VRRIJV 2 6.9k 14mo

Related topics — sharing the tags disputed, effect size, risk of bias

TopicParticipantsRepliesViewsActivity
Publication bias detection and its low power
On the subject in the title: Publication bias detection and its low power Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…
MAZLKK 2 3.2k 1d
Stability of BPC-157 in solution: what has been measured
Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with FLOW ( N Engl J Med , 2024) and finding the…
AKEFSS 2 805 30d
Follow-up: A supplier that answers analytical questions with restated claims
A supplier that answers analytical questions with restated claims — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than…
CCPYESTCB+74 82 2.8k 6mo
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURPASS-2 ( N…
MGJICLAIDO+75 81 2k 2y
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
HFITVAKLV+10 14 8.4k 16h